Precision BioSciences, Inc. (DTIL)

Precision BioSciences' stock has been impacted by a 1-for-30 reverse stock split on February 14th, 2024. The company reported a quarterly loss of $1.84 per share in Q3 2025, missing estimates, and revenues of $0.01 million, also missing estimates. Precision BioSciences announced a $75 million and a $70 million stock offering in November 2025. The company presented Phase 1 PBGENE-HBV data at AASLD The Liver Meeting® and clinical data from the ELIMINATE-B trial at HEP-DART 2025. Precision BioSciences' price target was decreased by 10.55% to $33.15. The stock price increased from $3.81 at the beginning of 2025 to $5.11 by November 2025, but decreased to $5.00 per share as of November 21, 2025.

Information explicitly detailing demand seasonality for Precision BioSciences, Inc.'s products and services is not readily available. However, platforms like Seeking Alpha offer tools to identify seasonal patterns in its stock performance.

Precision BioSciences, Inc. is a clinical-stage biotechnology company focused on developing genome editing technologies through its ARCUS® platform. The company develops in vivo gene editing therapies for genetic and infectious diseases, and ex vivo allogeneic CAR T therapies for cancer. Key programs include PBGENE-HBV for chronic hepatitis B virus, PBGENE-3243 for m.3243 associated mitochondrial myopathy, PBGENE-NVS for sickle cell and beta thalassemia diseases, PBGENE-DMD for Duchenne muscular dystrophy, PBGENE-LIVER, PBGENE-CNS, iECURE-OTC for ornithine transcarbamylase deficiency, and various allogeneic CAR T immunotherapies. The company also applies the ARCUS platform to develop food and nutrition products through collaborations.

Precision BioSciences, Inc. is headquartered in Durham, North Carolina, United States, and primarily develops its therapeutic products in the United States.

Precision BioSciences has a consensus rating of "Hold" from Wall Street analysts. MarketBeat's MarketRank™ scored Precision BioSciences higher than 58% of companies evaluated. The company's reputation has been affected by positive clinical trial results from the ELIMINATE-B trial, missed earnings and revenue estimates in the Q3 2025 earnings report, and a decline in revenue due to the conclusion of collaborative agreements.

The ownership structure of Precision BioSciences stock includes institutional investors holding approximately 9.43% to 37.99%, insiders owning approximately 3.44% to 4.50%, retail investors holding approximately 27% to 87.13%, and public companies holding approximately 3.33% of the stock. Major institutional owners include Bleichroeder LP, Lynx1 Capital Management LP, Tang Capital Management LLC, Vanguard Group Inc, and Renaissance Technologies LLC. CEO Michael Amoroso owns 0.9% of the company's shares.